1. Tumor Plasticity and Resistance to Immunotherapy.
- Author
-
Horn LA, Fousek K, and Palena C
- Subjects
- Animals, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cancer Vaccines administration & dosage, Cell Line, Tumor, Cell Plasticity drug effects, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Combined Modality Therapy methods, Disease Models, Animal, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm immunology, Drug Synergism, Epithelial-Mesenchymal Transition drug effects, Humans, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Molecular Targeted Therapy methods, Neoplasms immunology, Neoplasms pathology, Treatment Outcome, Tumor Escape drug effects, Tumor Escape immunology, Xenograft Model Antitumor Assays, Cell Plasticity immunology, Epithelial-Mesenchymal Transition immunology, Immunotherapy methods, Neoplasms therapy
- Abstract
Tumor cell plasticity exhibited as an epithelial-mesenchymal transition (EMT) has been identified as a major obstacle for the effective treatment of many cancers. This process, which involves the dedifferentiation of epithelial tumor cells towards a motile, metastatic, and mesenchymal tumor phenotype, mediates resistance to conventional therapies and small-molecule targeted therapies. In this review, we highlight current research correlating the role of tumor plasticity with resistance to current immunotherapy approaches and discuss future and ongoing combination immunotherapy strategies to reduce tumor cell plasticity-driven resistance in cancer., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF